AstraZeneca PLC - American Depositary Shares (AZN)
189.02
+0.61 (0.32%)
NYSE · Last Trade: Feb 3rd, 10:48 AM EST
Detailed Quote
| Previous Close | 188.41 |
|---|---|
| Open | 187.61 |
| Bid | 189.01 |
| Ask | 189.03 |
| Day's Range | 186.11 - 190.72 |
| 52 Week Range | 186.18 - 192.79 |
| Volume | 807,930 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | 0.9300 (0.49%) |
| 1 Month Average Volume | 3,228,415 |
Chart
About AstraZeneca PLC - American Depositary Shares (AZN)
AstraZeneca is a global biopharmaceutical company that focuses on the research, development, and manufacturing of a wide range of prescription medications. The company's primary areas of expertise include oncology, respiratory diseases, cardiovascular systems, and immunology, with a commitment to advancing innovative treatments that improve patient outcomes. AstraZeneca collaborates with healthcare professionals, researchers, and academic institutions to drive scientific advancements and ensure that their therapies reach those in need. Through its extensive portfolio, the company aims to address some of the world’s most pressing health challenges while maintaining a strong emphasis on sustainability and corporate responsibility. Read More
News & Press Releases
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for DATROWAY® (datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
By AstraZeneca · Via Business Wire · February 3, 2026
The U.S. economy faced a sobering reality check last week as the Bureau of Economic Analysis (BEA) released a trade report on January 29, 2026, revealing a deficit that widened far beyond initial expectations. While economists had penciled in a consensus forecast of -$43.4 billion, the final
Via MarketMinute · February 2, 2026
